Physician profile
Kelin E Schultz
NPI 1528265378
$696.52
in general payments reported to CMS, 2019-2025
14 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.94 · 2022: $57.21 · 2023: $297 · 2024: $145 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $173.01 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Axonics, INC. | $98.38 | 2022-2024 | Axonics |
| Boston Scientific Corporation | $76.10 | 2025 | Axonics |
| Hologic Sales and Service, LLC | $56.18 | 2019-2024 | Acessa Provu System, Novasure |
| Coopersurgical, INC. | $53.21 | 2023-2024 | Mara Console, Paragard T 380a, Endosee |
| Sage Therapeutics, LLC | $51.40 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $35.50 | 2024-2025 | |
| Exact Sciences Corporation | $35.39 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $29.77 | 2023 | Liletta |
| Exeltis, USA INC. | $21.89 | 2023 | Slynd |
| Astellas Pharma US INC | $18.57 | 2023 | Veozah |
| Ethicon US, LLC | $17.52 | 2022 | |
| Lilly USA, LLC | $15.85 | 2025 | Zepbound |
| Sumitomo Pharma America, INC. | $13.75 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelin Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.